NCT04914091Recruiting
Quality Of Life and Drug Use in Patients With CAR-T Cells
Pilot Study for Quality Of Life and Drug Use Assessment in Patients With CAR-T Cells
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
CAR-T cells are a major therapeutic innovation in the management of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in 3rd line or more. Kymriah® and Yescarta® are the first CAR-T with Marketing Authorization and coverage by the French Health Insurance. Their clinical interest has been demonstrated in non-comparative phase 1-2 trials. The non-comparative design of the pivotal trials, the lack of data on patients' quality of life and drug consumption, as well as the very high cost of CAR-T (about € 320,000 for one treatment) warrant further studies. This prospective non-comparative study aims to describe in real life the quality of life of patients treated with CAR-T cells, real world drug use and patients' experience feedback.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 31 May 2021
- Start date
- 31 Mar 2021
- Primary completion date
- 31 Jan 2033
- Lead sponsor
- Hospices Civils de Lyon
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT04914091
What you commit to
- Study type: Observational
- Planned participants: 70
- From 31 Mar 2021 to the primary completion date, 31 Jan 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- In an institution
- Under legal protection
Who the study is looking for
- Over 18 years old
- Eligible for treatment with CAR-T cells (outside any clinical trial) in an indication of DLBCL and for which treatment is scheduled
- Follow-up in the Hematology department of the Hospices Civils de Lyon
- Without major psychiatric disorder likely to interfere with the conduct of the study, in the opinion of the investigator
- Having given his non-opposition to participate in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospices Civils de Lyon -Groupement Hospitalier Sud Service pharmaceutique, Unité de Pharmacie Clinique Oncologique Coordinator of this site? Confirm its status | Pierre-Bénite | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.